Topotecan
- Generic Name
- Topotecan
- Brand Names
- Hycamtin, Potactasol, Topotecan Hospira
- Drug Type
- Small Molecule
- Chemical Formula
- C23H23N3O5
- CAS Number
- 123948-87-8
- Unique Ingredient Identifier
- 7M7YKX2N15
- Background
An antineoplastic agent used to treat ovarian cancer. It works by inhibiting DNA topoisomerases, type I.
- Indication
用于小细胞肺癌（SCLC）和一线治疗失败的晚期转移性卵巢癌。
- Associated Conditions
- Acute Myeloid Leukemia, Ewing's Sarcoma, Refractory Neuroblastoma, Metastatic Rhabdomyosarcoma, Recurrent Stage IVB Cervical Cancer, Refractory CNS lymphoma, Refractory CNS malignancy, Refractory, metastatic Ovarian cancer, Relapsed Platinum Sensitive Small Cell Lung Cancer (SCLC)
- Associated Therapies
- -
A Study of ALRN-6924 for the Prevention of Chemotherapy-induced Side Effects (Chemoprotection)
- Conditions
- Interventions
- First Posted Date
- 2019-07-17
- Last Posted Date
- 2022-10-10
- Lead Sponsor
- Aileron Therapeutics, Inc.
- Target Recruit Count
- 35
- Registration Number
- NCT04022876
- Locations
- 🇺🇸
Mount Sinai Cancer Research Program, Miami, Florida, United States
🇺🇸Regional Medical Oncolgy Center, Wilson, North Carolina, United States
🇺🇸Gabrail Cancer Institute, Canton, Ohio, United States
Intratumorally-Administered Topotecan Using Convection-Enhanced Delivery in Patients With Grade III/ IV Glioma
- First Posted Date
- 2019-04-25
- Last Posted Date
- 2023-05-25
- Target Recruit Count
- 3
- Registration Number
- NCT03927274
- Locations
- 🇺🇸
Moffitt Cancer Center, Tampa, Florida, United States
Dinutuximab, Sargramostim, and Combination Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma
- Conditions
- Interventions
- Procedure: Autologous Hematopoietic Stem Cell TransplantationDrug: CarboplatinDrug: CisplatinDrug: CyclophosphamideDrug: DexrazoxaneBiological: DinutuximabDrug: DoxorubicinDrug: EtoposideRadiation: External Beam Radiation TherapyDrug: IsotretinoinDrug: MelphalanBiological: SargramostimDrug: ThiotepaDrug: TopotecanDrug: Vincristine
- First Posted Date
- 2018-12-26
- Last Posted Date
- 2024-10-17
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 42
- Registration Number
- NCT03786783
- Locations
- 🇺🇸
Saint Jude Children's Research Hospital, Memphis, Tennessee, United States
🇳🇿Starship Children's Hospital, Grafton, Auckland, New Zealand
🇦🇺The Children's Hospital at Westmead, Westmead, New South Wales, Australia
A Phase 1b Study of Sevacizumab in Combination With Chemotherapy in Chinese Patients With Platinum-Resistant Recurrent Ovarian Cancer.
- First Posted Date
- 2018-12-04
- Last Posted Date
- 2018-12-04
- Lead Sponsor
- Jiangsu Simcere Pharmaceutical Co., Ltd.
- Target Recruit Count
- 48
- Registration Number
- NCT03763123
- Locations
- 🇨🇳
Hunan Cancer Hospital, Changsha, Hunan, China
🇨🇳Wuhan Union Hospital, Wuhan, Hunan, China
🇨🇳Beijing Cancer Hospital, Beijing, Beijing, China
Study Of Palbociclib Combined With Chemotherapy In Pediatric Patients With Recurrent/Refractory Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2018-10-17
- Last Posted Date
- 2024-08-09
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 128
- Registration Number
- NCT03709680
- Locations
- 🇨🇦
The Hospital for Sick Children, Toronto, Ontario, Canada
🇺🇸UPMC Children's Hospital of Pittsburgh, Pittsburgh, Pennsylvania, United States
🇺🇸Dana-Farber Cancer Institute, Boston, Massachusetts, United States
Clinical Trial of SP-2577 (Seclidemstat) in Patients With Relapsed or Refractory Ewing or Ewing-related Sarcomas
- Conditions
- Interventions
- First Posted Date
- 2018-07-26
- Last Posted Date
- 2023-11-21
- Lead Sponsor
- Salarius Pharmaceuticals, LLC
- Target Recruit Count
- 50
- Registration Number
- NCT03600649
- Locations
- 🇺🇸
Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States
🇺🇸Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸Sarcoma Oncology Research Center, Santa Monica, California, United States
M7824 and Topotecan or Temozolomide in Relapsed Small Cell Lung Cancers
- Conditions
- Interventions
- First Posted Date
- 2018-06-13
- Last Posted Date
- 2024-11-25
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 80
- Registration Number
- NCT03554473
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States
Real-World Effectiveness of Bevacizumab Based on AURELIA in Platinum-resistant Recurrent Ovarian Cancer
- Conditions
- Interventions
- First Posted Date
- 2017-12-08
- Last Posted Date
- 2019-01-11
- Lead Sponsor
- Yonsei University
- Target Recruit Count
- 50
- Registration Number
- NCT03367182
- Locations
- 🇰🇷
Severance hospital, Seoul, Korea, Republic of
Topotecan Hydrochloride and Carboplatin With or Without Veliparib in Treating Advanced Myeloproliferative Disorders and Acute Myeloid Leukemia or Chronic Myelomonocytic Leukemia
- Conditions
- Essential ThrombocythemiaAtypical Chronic Myeloid LeukemiaMyelodysplastic/Myeloproliferative NeoplasmMyelofibrosisAcute Myeloid LeukemiaAcute Myeloid Leukemia Arising From Previous Myelodysplastic SyndromeChronic Myelomonocytic LeukemiaPolycythemia VeraRecurrent Acute Myeloid LeukemiaRefractory Acute Myeloid Leukemia
- Interventions
- First Posted Date
- 2017-09-21
- Last Posted Date
- 2024-07-26
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 25
- Registration Number
- NCT03289910
- Locations
- 🇺🇸
Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore, Maryland, United States
🇺🇸USC Norris Oncology/Hematology-Newport Beach, Newport Beach, California, United States
🇺🇸Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States
Study in Patients With SCLC of Veliparib in Combination With Topotecan
- First Posted Date
- 2017-07-24
- Last Posted Date
- 2021-01-27
- Target Recruit Count
- 30
- Registration Number
- NCT03227016
- Locations
- 🇩🇪
Klinik München Gauting, München Gauting, Germany
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.